10x Genomics, Inc.
TXG$58.48
$-0.09 (-0.15%)-0.15%
ClosedLoading chart...
IndexN/A
Market Cap7.42B
Enterprise Value1.72B
Income$-0.03B
Sales$0.15B
EmployeesN/A
P/E-344.00
P/S3.17
P/B2.56
P/C15.64
EV/EBITDA439.61
EV/SalesN/A
EPS (ttm)-0.17
EarningsN/A
Gross Margin69.05%
Oper. Margin-17.25%
Profit Margin-6.77%
Volume4.31M
Shs Outstand0.13B
Change-0.15%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $610.78M | $618.73M | $516.41M | $490.49M | $298.85M | $245.89M | $146.31M | $71.08M |
| Cost of Revenue | $196.30M | $209.41M | $120.39M | $74.09M | $58.47M | $61.03M | $28.66M | $10.56M |
| Gross Profit | $414.48M | $409.31M | $396.02M | $416.40M | $240.38M | $184.86M | $117.65M | $60.52M |
| Gross Margin | 67.86% | 66.15% | 76.69% | 84.89% | 80.44% | 75.18% | 80.41% | 85.14% |
| Operating Expenses | $609.04M | $674.64M | $563.97M | $469.31M | $325.70M | $213.93M | $228.42M | $78.90M |
| Operating Income | $-194.56M | $-265.33M | $-167.94M | $-52.91M | $-85.32M | $-29.07M | $-110.76M | $-18.38M |
| Operating Margin | -31.85% | -42.88% | -32.52% | -10.79% | -28.55% | -11.82% | -75.70% | -25.85% |
| Net Income | $-182.63M | $-255.10M | $-166.00M | $-58.22M | $-542.73M | $-31.25M | $-112.48M | $-18.76M |
| Net Margin | -29.90% | -41.23% | -32.15% | -11.87% | -181.61% | -12.71% | -76.88% | -26.39% |
| EPS (Basic) | $-1.52 | $-2.18 | $-1.46 | $-0.53 | $-5.37 | $-0.80 | $-8.40 | $-1.62 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $918.64M | $965.14M | $1.03B | $1.02B | $929.34M | $605.92M | $124.31M | $75.61M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $208.50M | $224.10M | $223.24M | $201.26M | $190.27M | $185.84M | $344.30M | $188.12M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $710.13M | $741.04M | $805.74M | $817.57M | $739.07M | $420.08M | $-219.99M | $-112.51M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $710.13M | $741.04M | $805.74M | $817.57M | $739.07M | $420.08M | $-219.99M | $-112.51M |
| Total Liabilities & Stockholders Equity | $918.64M | $965.14M | $1.03B | $1.02B | $929.34M | $605.92M | $124.31M | $75.61M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-182.63M | $-255.10M | $-166.00M | $-58.22M | $-542.73M | $-31.25M | $-112.48M | $-18.76M |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $6.66M | $-15.20M | $-33.61M | $-21.37M | $-217.90M | $34.63M | $-76.41M | $-10.70M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
10x Genomics Q2 Earnings & Revenues Beat Estimates, Gross Margin Upzacks.com 10x Genomics Q2 Earnings Call Highlightsmarketbeat.com 10x Genomics, Inc. (TXG) Q2 2026 Earnings Call Transcriptseekingalpha.com 10x Genomics (TXG) Q2 Earnings: Taking a Look at Key Metrics Versus Estimateszacks.com 10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimateszacks.com 10x Genomics Reports Second Quarter 2026 Financial Resultsprnewswire.com 10x Genomics (TXG) Upgraded to Buy: Here's Whyzacks.com 10x Genomics (TXG) Expected to Beat Earnings Estimates: Can the Stock Move Higher?zacks.com
Show 12 more stories
10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer Careprnewswire.com 10x Genomics $TXG Shares Sold by Amova Asset Management Americas Inc.defenseworld.net Analyzing Mitesco (OTCMKTS:MITI) and 10x Genomics (NASDAQ:TXG)defenseworld.net 10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026prnewswire.com 10x Genomics, Cleveland Clinic Team Up on Bladder Cancer Diagnosticszacks.com Torex Gold Announces Results of Its 2026 Meeting of Shareholdersnewsfilecorp.com Torex Gold Resources Inc. (TXG:CA) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.com 10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder Cancerprnewswire.com TXG Gains From Proteintech Deal, Expands Multiomics Capabilitieszacks.com 10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech Groupprnewswire.com 10x Genomics, Inc. (TXG) Shareholder/Analyst Call Prepared Remarks Transcriptseekingalpha.com 10x Genomics CEO Sells Nearly 30,000 Shares. Here's What That Means for Investors.fool.com
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Discover more
You may be interested in